These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16450393)

  • 1. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.
    Cheung IY; Vickers A; Cheung NK
    Int J Cancer; 2006 Jul; 119(1):152-6. PubMed ID: 16450393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
    J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.
    Cheung IY; Feng Y; Vickers A; Gerald W; Cheung NK
    J Mol Diagn; 2007 Apr; 9(2):237-41. PubMed ID: 17384216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
    Cheung IY; Cheung NK
    Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
    Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
    Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
    Hoon DS; Kuo CT; Wen S; Wang H; Metelitsa L; Reynolds CP; Seeger RC
    Am J Pathol; 2001 Aug; 159(2):493-500. PubMed ID: 11485908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of polysialyltransferase expression during hippocampus development: Implications for neuronal survival.
    Brocco M; Pollevick GD; Frasch AC
    J Neurosci Res; 2003 Dec; 74(5):744-53. PubMed ID: 14635225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Cheung NK
    J Clin Oncol; 2003 Oct; 21(20):3853-8. PubMed ID: 14551304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.
    Bozzi F; Luksch R; Collini P; Gambirasio F; Barzanò E; Polastri D; Podda M; Brando B; Fossati-Bellani F
    Diagn Mol Pathol; 2004 Sep; 13(3):135-43. PubMed ID: 15322424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GD2 synthase: a new molecular marker for detecting neuroblastoma.
    Lo Piccolo MS; Cheung NK; Cheung IY
    Cancer; 2001 Aug; 92(4):924-31. PubMed ID: 11550167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
    Kuroda T; Saeki M; Nakano M; Mizutani S
    J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
    Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
    Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors.
    Corrias MV; Haupt R; Carlini B; Cappelli E; Giardino S; Tripodi G; Tonini GP; Garaventa A; Pistoia V; Pistorio A
    Pediatr Blood Cancer; 2012 Jan; 58(1):43-9. PubMed ID: 21254375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma.
    Fest S; Soldati R; Christiansen NM; Zenclussen ML; Kilz J; Berger E; Starke S; Lode HN; Engel C; Zenclussen AC; Christiansen H
    Int J Cancer; 2016 Apr; 138(8):2030-42. PubMed ID: 26595750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
    Cheung IY; Sahota A; Cheung NK
    Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
    Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma.
    Ito R; Asami S; Kagawa S; Motohashi S; Shichino H; Chin M; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
    Biol Pharm Bull; 2004 Mar; 27(3):315-8. PubMed ID: 14993794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.
    Cheung NK; Ostrovnaya I; Kuk D; Cheung IY
    J Clin Oncol; 2015 Mar; 33(7):755-63. PubMed ID: 25559819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma.
    Tchirkov A; Paillard C; Halle P; Bernard F; Bordigoni P; Vago P; Deméocq F; Kanold J
    J Hematother Stem Cell Res; 2003 Aug; 12(4):435-42. PubMed ID: 12965080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.
    Cheung IY; Feng Y; Gerald W; Cheung NK
    Clin Cancer Res; 2008 Nov; 14(21):7020-7. PubMed ID: 18980998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.